Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands ...

British pharmaceutical giant GSK has announced its acquisition of Nuvalent, a U.S.-listed cancer drug developer, for $10.6 ...

Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. Shares of Nuvalent jumped 39% to $122.90. GSK’s ...

By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer ...

GSK's $10.6 billion acquisition of Nuvalent marks a major shift in strategy under CEO Luke Miels. The deal, at a 40% premium, ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based firm, ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday.

GSK has plans to takeover Nuvalent, a Boston-based clinical-stage biopharmaceutical company for 10.6 billion dollars. The ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...

June 9 (Reuters) - British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent ...